Home » Topics » Regulatory » EMA

EMA
RSS

EMA completes validation of Dyax's MAA for ecallantide

July 7, 2010

Nycomed receives European marketing authorization for roflumilast in COPD

July 7, 2010

Circadin approved in the E.U. for 13-week treatment for primary insomnia

July 6, 2010

Rifapentine obtains orphan drug status in Europe for tuberculosis

July 2, 2010

EMA issues encouraging scientific advice on phase III perifosine trial in colorectal cancer

July 1, 2010

AMAG and Takeda begin global registrational program of ferumoxytol

July 1, 2010

EMA's CHMP issues positive opinion for Pharming's Rhucin

June 29, 2010

CHMP recommends approval of vernakalant for atrial fibrillation

June 29, 2010

CHMP confirms previous negative opinion for ceftobiprole

June 29, 2010

CHMP recommends approval of Sycrest for bipolar disorder

June 29, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026